2025
Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
Xu H, Aparicio C, Wats A, Araujo B, Pitzer V, Warren J, Shapiro E, Niccolai L, Weinberger D, Oliveira C. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open 2025, 8: e250380. PMID: 40063022, PMCID: PMC11894488, DOI: 10.1001/jamanetworkopen.2025.0380.Peer-Reviewed Original ResearchConceptsRSV-positive casesCase-control studyRSV infectionLRTI-associated hospitalizationsWeeks postimmunizationLong-acting monoclonal antibodiesTest-negative case-control studyClinical settingRespiratory syncytial virusMultivariate logistic regressionYale New Haven Health SystemRSV diseaseEmergency department dataState immunization registryRSV seasonSyncytial virusNirsevimabPolymerase chain reactionClinical trialsLRTIInfantsPotential confoundersMonoclonal antibodiesBroader outcomesDisease severity
1995
Office pediatrics
McCarthy P, Bachman D, Shapiro E, Baron M. Office pediatrics. Current Opinion In Pediatrics 1995, 7: 107-125. PMID: 7728195, DOI: 10.1097/00008480-199502000-00020.Commentaries, Editorials and LettersConceptsCommunity-acquired lower respiratory infectionsLower respiratory tract infectionsInfectious diseasesDiarrhea of infancyLower respiratory infectionsRespiratory tract infectionsPediatric office practiceRespiratory syncytial virusHemolytic uremic syndromeEvaluation of childrenDay care centersProlonged feverTract infectionsAcute feverRespiratory infectionsSyncytial virusClinical examinationCare centerEnterohemorrhagic Escherichia coliStreptococcus pneumoniaeUnknown originOffice settingOffice practiceInfectionAntimicrobial drugs
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply